Harvard Bioscience, Inc. (HBIO): Price and Financial Metrics
GET POWR RATINGS... FREE!
HBIO POWR Grades
- Growth is the dimension where HBIO ranks best; there it ranks ahead of 99.49% of US stocks.
- HBIO's strongest trending metric is Value; it's been moving down over the last 31 weeks.
- HBIO ranks lowest in Momentum; there it ranks in the 15th percentile.
HBIO Stock Summary
- Price to trailing twelve month operating cash flow for HBIO is currently 42.64, higher than 89.19% of US stocks with positive operating cash flow.
- Over the past twelve months, HBIO has reported earnings growth of -115.6%, putting it ahead of only 17.35% of US stocks in our set.
- In terms of volatility of its share price, HBIO is more volatile than 83.81% of stocks we're observing.
- Stocks that are quantitatively similar to HBIO, based on their financial statements, market capitalization, and price volatility, are UFI, ESTA, CLNE, VG, and HLIT.
- Visit HBIO's SEC page to see the company's official filings. To visit the company's web site, go to www.harvardbioscience.com.
HBIO Valuation Summary
- HBIO's price/sales ratio is 3.1; this is 13.89% lower than that of the median Healthcare stock.
- HBIO's price/sales ratio has moved down 4.7 over the prior 243 months.
- HBIO's price/sales ratio has moved down 4.7 over the prior 243 months.
Below are key valuation metrics over time for HBIO.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| HBIO | 2020-08-03 | 1.1 | 1.6 | -18.0 | -61.6 |
| HBIO | 2019-01-08 | 1.1 | 1.6 | -26.4 | -76.6 |
| HBIO | 2008-09-29 | 1.6 | 1.9 | -88.3 | 184.0 |
| HBIO | 2007-03-29 | 1.9 | 2.0 | -62.8 | -1026.3 |
| HBIO | 2006-01-25 | 1.8 | 2.0 | -6.0 | -8.0 |
| HBIO | 2003-01-31 | 1.8 | 1.3 | 70.8 | 17.8 |
HBIO Growth Metrics
- Its 2 year net cashflow from operations growth rate is now at 321.09%.
- The 4 year price growth rate now stands at -11.78%.
- Its 3 year price growth rate is now at -12.1%.
The table below shows HBIO's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2021-03-31 | 105.318 | 7.497 | -3.963 |
| 2020-12-31 | 102.1 | 9.331 | -7.81 |
| 2020-12-31 | 102.1 | 9.331 | -7.81 |
| 2020-09-30 | 102.088 | 9.061 | -6.645 |
| 2020-06-30 | 105.469 | 10.622 | -8.167 |
| 2020-03-31 | 111.745 | 8.906 | -6.833 |
HBIO Price Target
For more insight on analysts targets of HBIO, see our HBIO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $9.75 | Average Broker Recommendation | 1.38 (Strong Buy) |
HBIO Stock Price Chart Interactive Chart >
HBIO Price/Volume Stats
| Current price | $7.89 | 52-week high | $8.55 |
| Prev. close | $8.05 | 52-week low | $2.74 |
| Day low | $7.84 | Volume | 109,300 |
| Day high | $8.17 | Avg. volume | 231,726 |
| 50-day MA | $7.61 | Dividend yield | N/A |
| 200-day MA | $5.59 | Market Cap | 315.26M |
Harvard Bioscience, Inc. (HBIO) Company Bio
Harvard Bioscience, Inc. develops, manufactures, and markets scientific instruments, systems, and lab consumables used in life science research. The company was founded in 1901 and is based in Holliston, Massachusetts.
Latest HBIO News From Around the Web
Below are the latest news stories about Harvard Bioscience Inc that investors may wish to consider to help them evaluate HBIO as an investment opportunity.
Harvard Bioscience (HBIO) Reports Next Week: What to Know Ahead of the ReleaseHarvard Bioscience (HBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
Global Perfusion Market 2021 Future Set to Massive Growth with High CAGR value | Market Players: Getinge, Medtronic, LivaNova, Terumo Medical, Xenios, Lifeline Scientific, XVIVO Perfusion, Repligen Corporation, Spectrum Laboratories, Merck, Harvard Bioscience, Ala ScienceThe report on Global Perfusion Market has been provided by researchers for a detailed understanding of market performance over an estimated period of time set from 2021 to 2026. However, this report has introduced a brief overview to provide the reader with better information on this report. This brief description contains a basic definition of [] |
What Type Of Shareholders Make Up Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Share Registry?The big shareholder groups in Harvard Bioscience, Inc. ( NASDAQ:HBIO ) have power over the company. Generally speaking... |
Harvard Bioscience Schedules Second Quarter 2021 Earnings Conference Call for August 5, 2021 at 8:00 AM ETHOLLISTON, Mass., July 19, 2021 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for second quarter ended June 30, 2021 before the market opens on August 5, 2021, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time. |
10 Best Stocks Under $10 to Buy Right NowIn this article, we will be looking at the 10 best stocks under $10 to buy right now. If you want to skip our detailed analysis on these companies, you can go directly to the 5 Best Stocks Under $10 to Buy Right Now. Investing in cheap stocks can lead to financial success given that […] |
HBIO Price Returns
| 1-mo | -4.13% |
| 3-mo | 13.04% |
| 6-mo | 64.72% |
| 1-year | 153.70% |
| 3-year | 37.22% |
| 5-year | 178.80% |
| YTD | 83.92% |
| 2020 | 40.66% |
| 2019 | -4.09% |
| 2018 | -3.64% |
| 2017 | 8.20% |
| 2016 | -12.10% |
Continue Researching HBIO
Want to see what other sources are saying about Harvard Bioscience Inc's financials and stock price? Try the links below:Harvard Bioscience Inc (HBIO) Stock Price | Nasdaq
Harvard Bioscience Inc (HBIO) Stock Quote, History and News - Yahoo Finance
Harvard Bioscience Inc (HBIO) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...